Brezivaptan
A vasopressin receptor antagonist
| Brezivaptan | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Brezivaptan is a pharmaceutical compound that acts as a selective antagonist of the vasopressin receptor V1A. It is primarily investigated for its potential therapeutic applications in conditions where modulation of vasopressin activity is beneficial.
Pharmacology
Brezivaptan functions by inhibiting the action of vasopressin, a hormone that plays a crucial role in regulating water retention, blood pressure, and vascular resistance. By blocking the V1A receptor, Brezivaptan can potentially reduce vasoconstriction and lower blood pressure, making it a candidate for treating hypertension and other cardiovascular disorders.
Mechanism of Action
The mechanism of action of Brezivaptan involves selective antagonism of the V1A receptor, one of the subtypes of vasopressin receptors. The V1A receptor is predominantly found in vascular smooth muscle cells and the central nervous system. By blocking this receptor, Brezivaptan prevents vasopressin from exerting its vasoconstrictive effects, leading to vasodilation and a subsequent decrease in blood pressure.
Clinical Applications
Brezivaptan is being studied for its potential use in treating conditions such as congestive heart failure, where fluid overload and increased vascular resistance are common issues. Its ability to modulate vasopressin activity without affecting the V2 receptor, which is responsible for water reabsorption in the kidneys, makes it a promising candidate for managing fluid balance without causing significant diuresis.
Development and Research
Research on Brezivaptan is ongoing, with studies focusing on its efficacy, safety, and potential side effects. The development of Brezivaptan is part of a broader effort to create selective vasopressin receptor antagonists that can provide therapeutic benefits with minimal adverse effects.
Related pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian